In the last twelve months, the pharmaceutical industry’s lightening response to the Covid-19 pandemic, with the production of effective vaccines, has demonstrated the brilliance of science and helped the sector shake-off a poor profile.
The herculean task of vaccinating the entire planet has commenced, but the scale of this logistical test means the roll-out will take years. Initial progress has been slow and uneven, and the increasing number of emerging new variants is raising questions about the long-term effectiveness of the vaccines being issued.
The pandemic may have presented an opportunity for Big Pharma to showcase its contribution to mankind, but can its reputation be changed for good?
Beleaguered starting point
In September 2019, a US Gallup survey reported that the Pharmaceutical industry is “the most poorly regarded (sector) in Americans’ eyes.” Ranking last on a list of 25 industries1, the US public had an extremely poor perception of the sector. Similar, opinions could be found in other parts of the world, especially among developed nations.
Much of this criticism stemmed from allegations of overcharging for drugs, with pharmaceutical companies being depicted as self-serving profiteers with little in the way of a social conscience. President Trump frequently railed against the industry during his presidency, while the Biden administration has indicated it would attempt to reduce drug prices. Anti-vaccination propaganda was also rife prior to the pandemic, with a rise in measles being attributed to low uptake of the available vaccination and the World Health Organisation (WHO) naming vaccine hesitancy as one of the ten biggest threats to global health2.
A spectacular transformation
When the WHO confirmed that the Covid-19 outbreak was a pandemic in March 2020, few would have thought a vaccine would be ready, approved and in use by the end of the year. However, scientists got to work quickly and phase 1 trials of the Oxford/AstraZeneca and Pfizer/BioNTech vaccines commenced in Spring 2020. By November, these vaccines had both demonstrated tolerable levels of efficacy and moved on to the approval stage worldwide.
The pace of this response was truly breathtaking. In fact, it has been the fastest vaccine development ever. To provide some perspective, clinical trials take an average 6-7 years, with subsequent time needed for regulatory approval.
An uneven vaccine roll-out
So far, over 8.5 billion3 doses of the vaccine have been pre-ordered which is technically enough to cover half the world’s population (assuming most vaccines require two doses). Moreover, in early February the number of Covid-19 vaccinations administered worldwide surpassed the total number of confirmed cases, of over 100 million4. This is an encouraging start, but the world has a very long way to go before the virus is tamed.
The logistical complexity of vaccinating the whole planet cannot be underestimated, let alone the cost of this exercise. Therefore, it is unsurprising that wealthy nations are topping the global vaccination roll-out rankings. The stability of the supply chain is currently the number one concern and even developed nations are not immune to these fears. The European Union faced accusations of vaccine protectionism when it threatened to control the exports of EU-manufactured vaccines amid concerns over its own supplies.
The sharp skew of vaccination rates towards more affluent nations had been called out by the head of the WHO, who warned the world was on the brink of a “catastrophic moral failure” if more wasn’t done to support the poorest countries. Last year, the WHO formed the COVAX organisation to try and ensure equitable distribution. So far COVAX has only managed to secure half of its target to provide 2 billion vaccine doses for free, or at a reduced cost. However, wealthy nations, such as the UK, have stated that if they have surplus supply, then they intend to contribute this supply to initiatives supporting vaccinations programmes in poorer countries.
Similarly, the dissemination of vaccines to the poorer areas of the world would be vastly accelerated if the companies behind the vaccines were prepared to waive their intellectual property rights in certain geographies. This is being resisted so far but could deliver a decisive boost for the reputation of the sector.
A profit-making opportunity?
The costs of drugs, and the profit-making ability of pharmaceutical companies, has been at the heart of the industry’s poor reputation and the profit-making potential of the Covid-19 vaccine will be closely scrutinised. Of the three initial vaccines to be approved, the UK’s AstraZeneca is currently the cheapest at around $4 per dose, with the company stating this low price merely covers its costs and will remain low for the duration of the pandemic. US biotech firm Moderna has priced its vaccine at $37 per dose, while the BioNtech/Pfizer is priced at $19.50 per dose. Neither of these companies have committed to AstraZeneca’s not-for-profit pledge and the BioNtech/Pfizer collaboration is set to generate $13 billion (£9.8 billion) in global sales for its vaccine, according to Morgan Stanley5.
It is also important to acknowledge that these scientific breakthroughs were achieved thanks to billions in government and philanthropic backing. According to science data analytics company Airfinity, governments provided £6.5 billion to Covid-19 vaccine research, while not-for-profit organisations donated nearly £1.5 billion6.
Obviously, pharmaceutical businesses have a right to make a profit from their achievements, but at what point does rewarding success turn to profiteering, particularly when public funding has been involved?
To vaccinate or not to vaccinate…
Aside from the pharmaceutical companies themselves, the concept of vaccination also has a substantial public relations hurdle to surpass. While a 2020 study of coronavirus acceptance, reported in Nature Medicine and conducted across 19 countries, showed an average world acceptance level of 71.5%, there were considerable variations by country7. European nations, such as France, Poland and Russia were shown to be particularly sceptical, with acceptance levels at 59%, 56% and 55% respectively.
The implications of this vaccine hesitancy are significant. As many commentators have said, the only way we are going to beat the virus is to beat it together. Governments will need to work hard to counter the vast swathes of misinformation being circulated online if true herd immunity is to be achieved.
The variant challenge
While an increasing number of vaccines have been proven effective, the task for the drug makers is not over yet. The emergence of new strains of Sars-Cov-2, the virus that causes Covid-19, or ‘new variants’, is creating fresh worries about the long-term efficacy of vaccines.
Scientists have expressed confidence that vaccines can be adjusted quickly, but there are still implications for the wider public. Will the virus mutate quickly enough to make the existing vaccines obsolete? How long will vaccines confer immunity for? Will regular re-vaccinations be required (as with the flu)? This latter scenario raises the stupefying, yet increasingly likely, prospect of whether the world will need to be vaccinated annually and how this would be funded.
Pharmaceutical heroism
Despite this list of unanswerable questions, one thing is absolutely clear: the dedication of governments, philanthropists, health services and, notably, the pharmaceutical companies behind the rapid production of Covid-19 vaccinations are to be applauded.
Pandemics are not unprecedented, but modern medicine has shown it is better equipped than ever before to combat them. And this outcome presents an excellent shop window for what can be achieved when these parties collaborate and unite in a common aim.
Whether its tackling the disruption of this pandemic, or tackling future health crises, healthcare is evolving quickly and the pharmaceutical industry is at the forefront of these disruptive innovations. At BNP Paribas Asset Management, we believe that where there is disruption there is opportunity. This is why we will continue to look under the surface so that we can spot these opportunities for our investors to not just achieve long-term investment returns, but also to invest for the good of wider society.
To find out more about the investment themes discussed here, please complete the form below.
SUBSCRIBE
Get insights straight to your inbox.
Information dedicated to professional investors
This website is launched and published by BNP Paribas Asset Management, as defined at the bottom of every page of the website (the “Company”) Opinions on this website are the judgement of the Company, at the time specified and may be subject to change without notice. The Company is not obliged to update or alter the information or opinions published on this website.
By accepting this disclaimer as set out below, you acknowledge its content as being the mutually agreed terms for your visit of and the use of this website. Whereas the term “website” includes all content and data provided and all sub- and micro-sites of this website. Further, as a user of this website, you acknowledge, that you are responsible for ensuring that the legislation applicable to you in your jurisdiction permits you to consult this website and you represent and warrant that you have the necessary means and skills to access this website and use it in the intended manner only. This disclaimer is subject to changes without prior notice. If any of the provisions of this disclaimer are judged to be illegal or unenforceable, the continuation in full force and effect of the remainder of them will not be prejudiced.
Certain sections and / or pages of this website contain separate and / or supplementary conditions, including separate disclaimers, which apply in addition to this disclaimer and any separate and / or supplementary conditions. In the event of discrepancy between this disclaimer and any separate and / or supplementary conditions, the separate and / or supplementary conditions relating to the sections or pages of this website will take precedence.
Site Contents
The information provided on this website is for general information purposes only. It is not intended to solicit the subscription of or the sale of any financial instruments, products or services. In no event shall the content of this website be deemed to be investment advice with respect to any financial instruments or investment services. In addition, the presentation of any information on financial instruments or investment services in itself does not allow the making of a contract and should not be construed as an offer or placement of any financial instruments, or solicitation for the purchase or sale of any financial or investment services to any persons in any jurisdiction.
The Company is authorised and regulated by the Financial Conduct Authority as an investment firm. The Company does not offer or purport to offer any direct lending or credit facilities to UK borrowers in connection with the SME Advanced Solutions platform or otherwise. Any potential borrowers should note that non-consumer loans and similar credit facilities are not regulated investments under applicable UK law and that non-consumer lending is not a regulated activity in the UK.
The Company disclaims any liability for any decision made on the basis of any information contained on this website. Potential investors and other market participants are encouraged to consult their own investment or financial advisers in connection with the purchase of any financial instruments or investment services or the entry into any borrowing or similar arrangements.
Exclusion of Liability
The Company including its parent company, subsidiaries, associated entities, directors, employees, representatives or suppliers, does not accept any responsibility arising in any way for errors in omissions from the information on this website and does not accept any liability for any loss or damage as a result of any person relying on any information on this website including any information provided by any third parties or by any inability to access this website at any time, except in the event of intentional or serious blame on its part.
Sources
All externally sourced information has been obtained from providers believed to be reliable, but its accuracy, timeliness, suitability and completeness is not guaranteed. For further information on fund(s), please contact the Company.
Links
This website may also contain links to websites which are published by third parties and third party websites may also feature links to this website. The Company has not reviewed any third party websites which refer to this website or to which this website refers for accuracy, topicality and / or completeness. The Company declines any liability in this matter. The fact that a link has been created to a third party website or that permissions have been given to a third party website to contain a link to this website, in no way means that the Company approves or recommends neither any content nor any products or services offered on a third party website. If you visit a third party website by following a link on this website this will be at your own risk.
Intellectual Property Rights
The information and data featured on this website is protected by law. Copyright and other intellectual property rights on this website (including registered and unregistered trademarks, brands, texts, graphics, logos, icons, sound recordings, software, etc.) are owned and licensed by the Company. You may use and / or print off the data solely for the purpose of personal, non-commercial use. You may not in any form or by any means:
• adapt, reproduce, store, distribute, print, display, perform, publish or create derivative works from any part of this website; or
• commercialize any information, financial instruments or investment services obtained from any part of this website;
• use any registered or unregistered trademarks from this website;
without the express prior written consent of the Company.
Privacy Regulations
By visiting this website, information on the access (e.g. date, visited sites, duration, IP-address) can be registered. Such data will be used in accordance with Cookies Policy of the website and will not be passed on to third parties neither for commercial nor for non-commercial reasons. By accessing this website you hereby agree, that the Company and its affiliates may record and process any personal data that you submit and which relates to you for the following purposes: customer management, including new business prospects, management of the contractual relationship, the prevention of irregularities, generating statistics and tests,. You also agree that this data may be passed on to all entities associated with the Company for the same purposes or to other persons in order to comply with any statutory obligation, or in the event of legal interests. You also agree with such notification, should the receiving person or entity be located outside the European Union, regardless of whether an adequate level of protection can be guaranteed for personal data in the country of receipt.
Within the Company and its affiliates, access to any of your personal data is restricted to those persons who need this data in order to fulfil their duties.
Electronic Mail Function
The option to use email to contact the Company is just one of the convenient features offered by the Company. You will be aware of the limitations regarding the reliability of sending and receiving emails, as well as the accuracy and security of email traffic, so you will understand that the Company cannot be held liable for any loss or damage arising as a consequence of queries which are not received, confirmed or processed, or as a result of the fact that your email may be intercepted by third parties. As a result you are expressly advised not to send any sensitive information via email, because it may not be secure. However, if you do so, it will be at your own risk.
Applicable legislation and jurisdiction in law
Your access to, visit to and / or use of this website and this disclaimer are governed by and will be interpreted in accordance with France legislation. The courts of France shall have sole jurisdiction regarding any dispute in this regard, notwithstanding the fact that the Company may choose another court that has jurisdiction regarding a similar dispute in accordance with an applicable item of legislation.